188 related articles for article (PubMed ID: 18779644)
1. A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major.
Najafipour F; Aliasgarzadeh A; Aghamohamadzadeh N; Bahrami A; Mobasri M; Niafar M; Khoshbaten M
Ann Saudi Med; 2008; 28(5):361-6. PubMed ID: 18779644
[TBL] [Abstract][Full Text] [Related]
2. Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria.
Yassouf MY; Alquobaili F; Kabalan Y; Mukhalalaty Y
Hemoglobin; 2019 May; 43(3):218-221. PubMed ID: 31373517
[TBL] [Abstract][Full Text] [Related]
3. The impact of genotype on endocrine complications in thalassaemia major.
Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
[TBL] [Abstract][Full Text] [Related]
4. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia.
Kurtoglu AU; Kurtoglu E; Temizkan AK
Endokrynol Pol; 2012; 63(4):260-3. PubMed ID: 22933160
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
[TBL] [Abstract][Full Text] [Related]
6. Growth and endocrine function in thalassemia major in childhood and adolescence.
Delvecchio M; Cavallo L
J Endocrinol Invest; 2010 Jan; 33(1):61-8. PubMed ID: 20203539
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major.
Moayeri H; Oloomi Z
Arch Iran Med; 2006 Oct; 9(4):329-34. PubMed ID: 17061604
[TBL] [Abstract][Full Text] [Related]
8. Relation between BMD and biochemical, transfusion and endocrinological parameters in pediatric thalassemic patients.
Mohseni F; Mohajeri-Tehrani MR; Larijani B; Hamidi Z
Arch Osteoporos; 2014; 9():174. PubMed ID: 24652076
[TBL] [Abstract][Full Text] [Related]
9. Spectrum Of HBB Gene Variants And Major Endocrine Complications In Thalassemia Patients Of Pakistan.
Ghafoor MB; Ujjan ID; Waryah AM; Memon FA
J Pak Med Assoc; 2023 Oct; 73(10):2013-2016. PubMed ID: 37876062
[TBL] [Abstract][Full Text] [Related]
10. Endocrine complications in patients with Thalassaemia Major.
Toumba M; Sergis A; Kanaris C; Skordis N
Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
[TBL] [Abstract][Full Text] [Related]
11. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
Sharma R; Seth A; Chandra J; Gohain S; Kapoor S; Singh P; Pemde H
Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
[TBL] [Abstract][Full Text] [Related]
12. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
13. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
De Sanctis V; Roos M; Gasser T; Fortini M; Raiola G; Galati MC;
J Pediatr Endocrinol Metab; 2006 Apr; 19(4):471-80. PubMed ID: 16759032
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry.
Wajnrajch MP; Gertner JM; Huma Z; Popovic J; Lin K; Verlander PC; Batish SD; Giampietro PF; Davis JG; New MI; Auerbach AD
Pediatrics; 2001 Apr; 107(4):744-54. PubMed ID: 11335753
[TBL] [Abstract][Full Text] [Related]
15. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of growth, puberty and endocrine dysfunctions in relation to iron overload in multi transfused Indian thalassemia patients.
Merchant RH; Shirodkar A; Ahmed J
Indian J Pediatr; 2011 Jun; 78(6):679-83. PubMed ID: 21234716
[TBL] [Abstract][Full Text] [Related]
17. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
18. Thyroid function in thalassaemia major.
Senanayake MP; Suraweera SA; Hubert HD
Ceylon Med J; 1999 Dec; 44(4):166-8. PubMed ID: 10895267
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
Karamifar H; Shahriari M; Sadjadian N
East Mediterr Health J; 2003; 9(1-2):55-60. PubMed ID: 15562733
[TBL] [Abstract][Full Text] [Related]
20. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
Soliman AT; Yassin MA; De Sanctis V
Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
